Broad screening test for sphingolipid-storage diseases

Chii Shiarng Chen, Marc C. Patterson, Christine L. Wheatley, John F. O'Brien, Richard E. Pagano

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Background. Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods. We used a fluorescent analogue of lactosylceramide, called N-(5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl)-D -lactosylsphingosine (BODiPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings. During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM2 gangliosidosis, GM2 gangliosidosis (Tay-Sachs Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2% (95% CI 80.4-99.9) and the specificity 90.0% (68.3-98.8). Interpretation. This method may be useful as an general screen for lipid-storage diseases, modification, could used for large-scale be screening of drugs to abrogate lysosomal various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.

Original languageEnglish (US)
Pages (from-to)901-905
Number of pages5
JournalLancet
Volume354
Issue number9182
DOIs
StatePublished - Sep 11 1999

Fingerprint

Sphingolipidoses
GM2 Gangliosidosis
Lipids
Sphingolipid Activator Proteins
Type B Niemann-Pick Disease
Type A Niemann-Pick Disease
Type C Niemann-Pick Disease
Mucolipidoses
Metachromatic Leukodystrophy
Lipidoses
Fabry Disease
Cell Line
Preclinical Drug Evaluations
Protein Precursors
Golgi Apparatus
Cerebral Palsy
Lysosomes
Psychiatry
Dementia
Fibroblasts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chen, C. S., Patterson, M. C., Wheatley, C. L., O'Brien, J. F., & Pagano, R. E. (1999). Broad screening test for sphingolipid-storage diseases. Lancet, 354(9182), 901-905. https://doi.org/10.1016/S0140-6736(98)10034-X

Broad screening test for sphingolipid-storage diseases. / Chen, Chii Shiarng; Patterson, Marc C.; Wheatley, Christine L.; O'Brien, John F.; Pagano, Richard E.

In: Lancet, Vol. 354, No. 9182, 11.09.1999, p. 901-905.

Research output: Contribution to journalArticle

Chen, CS, Patterson, MC, Wheatley, CL, O'Brien, JF & Pagano, RE 1999, 'Broad screening test for sphingolipid-storage diseases', Lancet, vol. 354, no. 9182, pp. 901-905. https://doi.org/10.1016/S0140-6736(98)10034-X
Chen CS, Patterson MC, Wheatley CL, O'Brien JF, Pagano RE. Broad screening test for sphingolipid-storage diseases. Lancet. 1999 Sep 11;354(9182):901-905. https://doi.org/10.1016/S0140-6736(98)10034-X
Chen, Chii Shiarng ; Patterson, Marc C. ; Wheatley, Christine L. ; O'Brien, John F. ; Pagano, Richard E. / Broad screening test for sphingolipid-storage diseases. In: Lancet. 1999 ; Vol. 354, No. 9182. pp. 901-905.
@article{080135bbf1f2466b8d794a43118f506e,
title = "Broad screening test for sphingolipid-storage diseases",
abstract = "Background. Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods. We used a fluorescent analogue of lactosylceramide, called N-(5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl)-D -lactosylsphingosine (BODiPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings. During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM2 gangliosidosis, GM2 gangliosidosis (Tay-Sachs Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2{\%} (95{\%} CI 80.4-99.9) and the specificity 90.0{\%} (68.3-98.8). Interpretation. This method may be useful as an general screen for lipid-storage diseases, modification, could used for large-scale be screening of drugs to abrogate lysosomal various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.",
author = "Chen, {Chii Shiarng} and Patterson, {Marc C.} and Wheatley, {Christine L.} and O'Brien, {John F.} and Pagano, {Richard E.}",
year = "1999",
month = "9",
day = "11",
doi = "10.1016/S0140-6736(98)10034-X",
language = "English (US)",
volume = "354",
pages = "901--905",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9182",

}

TY - JOUR

T1 - Broad screening test for sphingolipid-storage diseases

AU - Chen, Chii Shiarng

AU - Patterson, Marc C.

AU - Wheatley, Christine L.

AU - O'Brien, John F.

AU - Pagano, Richard E.

PY - 1999/9/11

Y1 - 1999/9/11

N2 - Background. Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods. We used a fluorescent analogue of lactosylceramide, called N-(5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl)-D -lactosylsphingosine (BODiPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings. During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM2 gangliosidosis, GM2 gangliosidosis (Tay-Sachs Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2% (95% CI 80.4-99.9) and the specificity 90.0% (68.3-98.8). Interpretation. This method may be useful as an general screen for lipid-storage diseases, modification, could used for large-scale be screening of drugs to abrogate lysosomal various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.

AB - Background. Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods. We used a fluorescent analogue of lactosylceramide, called N-(5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl)-D -lactosylsphingosine (BODiPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings. During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM2 gangliosidosis, GM2 gangliosidosis (Tay-Sachs Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2% (95% CI 80.4-99.9) and the specificity 90.0% (68.3-98.8). Interpretation. This method may be useful as an general screen for lipid-storage diseases, modification, could used for large-scale be screening of drugs to abrogate lysosomal various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.

UR - http://www.scopus.com/inward/record.url?scp=0033546958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033546958&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(98)10034-X

DO - 10.1016/S0140-6736(98)10034-X

M3 - Article

C2 - 10489949

AN - SCOPUS:0033546958

VL - 354

SP - 901

EP - 905

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9182

ER -